Lifesci Capital Upgrades Janux Therapeutics (NASDAQ:JANX) to Strong-Buy

Janux Therapeutics (NASDAQ:JANX) was upgraded by investment analysts at Lifesci Capital to a “strong-buy” rating in a research note issued to investors on Friday,Zacks.com reports.

Several other equities research analysts also recently weighed in on the stock. Stifel Nicolaus upped their price objective on shares of Janux Therapeutics from $70.00 to $115.00 and gave the stock a “buy” rating in a report on Tuesday, December 3rd. Leerink Partners upped their price target on shares of Janux Therapeutics from $79.00 to $91.00 and gave the stock an “outperform” rating in a research note on Tuesday, December 3rd. UBS Group began coverage on shares of Janux Therapeutics in a research note on Thursday, October 24th. They set a “buy” rating and a $69.00 price objective on the stock. Cantor Fitzgerald restated an “overweight” rating and issued a $200.00 target price on shares of Janux Therapeutics in a research report on Wednesday, December 11th. Finally, Leerink Partnrs raised Janux Therapeutics to a “strong-buy” rating in a research note on Friday, November 22nd. One equities research analyst has rated the stock with a hold rating, ten have assigned a buy rating and two have assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Buy” and an average target price of $89.90.

Janux Therapeutics Trading Down 1.9 %

NASDAQ JANX opened at $54.10 on Friday. The company has a 50-day moving average price of $54.43 and a two-hundred day moving average price of $47.43. The stock has a market cap of $2.84 billion, a price-to-earnings ratio of -46.24 and a beta of 3.29. Janux Therapeutics has a 52 week low of $7.79 and a 52 week high of $71.71.

Janux Therapeutics (NASDAQ:JANX) last posted its earnings results on Wednesday, November 6th. The company reported ($0.51) EPS for the quarter, missing the consensus estimate of ($0.33) by ($0.18). Janux Therapeutics had a negative net margin of 463.91% and a negative return on equity of 10.47%. The business had revenue of $0.44 million during the quarter, compared to analyst estimates of $1.50 million. The business’s quarterly revenue was down 82.6% on a year-over-year basis. As a group, equities research analysts expect that Janux Therapeutics will post -1.35 earnings per share for the current fiscal year.

Insider Activity at Janux Therapeutics

In other Janux Therapeutics news, CEO David Alan Campbell sold 25,000 shares of the firm’s stock in a transaction dated Tuesday, December 24th. The shares were sold at an average price of $56.19, for a total value of $1,404,750.00. Following the completion of the transaction, the chief executive officer now directly owns 217,054 shares in the company, valued at $12,196,264.26. This trade represents a 10.33 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Also, Director Ra Capital Management, L.P. purchased 1,200,000 shares of the business’s stock in a transaction dated Friday, October 18th. The shares were purchased at an average price of $44.75 per share, for a total transaction of $53,700,000.00. Following the acquisition, the director now directly owns 9,317,246 shares of the company’s stock, valued at $416,946,758.50. This trade represents a 14.78 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders sold 92,801 shares of company stock worth $5,174,735 in the last quarter. 29.40% of the stock is owned by company insiders.

Institutional Trading of Janux Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of JANX. Franklin Resources Inc. grew its position in Janux Therapeutics by 64.5% during the third quarter. Franklin Resources Inc. now owns 18,983 shares of the company’s stock valued at $937,000 after purchasing an additional 7,442 shares in the last quarter. Virtu Financial LLC increased its stake in shares of Janux Therapeutics by 48.0% in the third quarter. Virtu Financial LLC now owns 7,463 shares of the company’s stock worth $339,000 after acquiring an additional 2,419 shares during the last quarter. Neo Ivy Capital Management purchased a new stake in shares of Janux Therapeutics during the third quarter worth $940,000. Geode Capital Management LLC raised its holdings in shares of Janux Therapeutics by 6.2% during the third quarter. Geode Capital Management LLC now owns 662,594 shares of the company’s stock worth $30,107,000 after acquiring an additional 38,490 shares in the last quarter. Finally, Barclays PLC boosted its position in Janux Therapeutics by 496.5% during the third quarter. Barclays PLC now owns 174,061 shares of the company’s stock valued at $7,907,000 after purchasing an additional 144,883 shares during the last quarter. Institutional investors and hedge funds own 75.39% of the company’s stock.

Janux Therapeutics Company Profile

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.